Array BioPharma Company Description
Array BioPharma is discovering it's best to be your own boss. Once devoted to discovering drug candidates for other firms, the company is increasingly focused on its own drug development efforts in the areas of cancer and inflammatory disease. Candidates in early clinical trials include potential therapies for breast cancer (ARRY-543) and rheumatoid arthritis (ARRY-162). Array has also out-licensed some cancer programs to AstraZeneca and Genentech; ARRY-886, developed with AstraZeneca, is in clinical trials for melanoma. Drug discovery services for third parties still account for a big chunk of business; Array has R&D agreements with InterMune, Ono Pharmaceutical, Celgene, and others.
View the Comprehensive Company Description for Array BioPharma
The Company Description provides a historical perspective of Array BioPharma's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Array BioPharma's evolution in the marketplace.
